Oral oncology · 2026
Effect of erlotinib and celecoxib as short-course neoadjuvant therapy in operable oral cavity squamous cell carcinoma: a randomized controlled window-of-opportunity trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nair Sudhir, Inchanalkar Mayuri, Chavdaa Rinal, Joshi Amit, Patil Vijay, Noronha Vanita, Prabhash Kumar, Mahajan Abhishek, Sable Nilesh, Janu Amit, Rane Swapnil, Patil Asawari, Sinha Shwetabh, Sameema V V, Sonawane Kavita, Nair Deepa, Agarwal J P, Laskar Sarbani, Gupta Tejpal, D'Cruz Anil K, Chaukar Devendra, Pai Prathmesh S, Mahimkar Manoj, Chaturvedi Pankaj
Аннотация
BACKGROUND: Delays in definitive surgery for operable oral cavity squamous cell carcinoma (OCSCC) may allow tumor progression. This randomized phase II trial evaluated a short-course neoadjuvant combination of erlotinib and celecoxib during the preoperative waiting period.
METHODS: Sixty-three patients with resectable OCSCC were randomized to celecoxib, erlotinib, combination therapy, or observation for 21 days before surgery. The primary endpoint was biomarker modulation; secondary endpoints were tumor response, safety, and feasibility. Biomarker modulation was analyzed using two-way ANCOVA of post-treatment levels adjusted for baseline expression. Clinical and radiological changes in the longest tumor dimension (LTD) were assessed.
RESULTS: Erlotinib exposure was independently associated with significant reductions in CD31 (p < 0.001), CD34 (p = 0.006), and cytoplasmic AKT (p = 0.006). Celecoxib exposure was also associated with reduced CD31 expression (p = 0.003). No significant effects were observed on EGFR, COX-2, CD44, HIF1α, or PI3K. Erlotinib-containing regimens reduced or stabilized tumor size, whereas the observation arm showed tumor progression during the wait time for surgery. Partial clinical responses occurred in 43.7% with erlotinib and 60% with combination therapy. Toxicities were predominantly grade 1-2, mainly acneiform rash and transient hepatic dysfunction, and did not delay surgery. Combination therapy showed a trend toward reduced angiogenesis.
CONCLUSIONS: Short-course neoadjuvant erlotinib, particularly with celecoxib, is feasible, safe, and biologically active in operable OCSCC, supporting further evaluation to prevent progression during unavoidable surgical delays.
METHODS: Sixty-three patients with resectable OCSCC were randomized to celecoxib, erlotinib, combination therapy, or observation for 21 days before surgery. The primary endpoint was biomarker modulation; secondary endpoints were tumor response, safety, and feasibility. Biomarker modulation was analyzed using two-way ANCOVA of post-treatment levels adjusted for baseline expression. Clinical and radiological changes in the longest tumor dimension (LTD) were assessed.
RESULTS: Erlotinib exposure was independently associated with significant reductions in CD31 (p < 0.001), CD34 (p = 0.006), and cytoplasmic AKT (p = 0.006). Celecoxib exposure was also associated with reduced CD31 expression (p = 0.003). No significant effects were observed on EGFR, COX-2, CD44, HIF1α, or PI3K. Erlotinib-containing regimens reduced or stabilized tumor size, whereas the observation arm showed tumor progression during the wait time for surgery. Partial clinical responses occurred in 43.7% with erlotinib and 60% with combination therapy. Toxicities were predominantly grade 1-2, mainly acneiform rash and transient hepatic dysfunction, and did not delay surgery. Combination therapy showed a trend toward reduced angiogenesis.
CONCLUSIONS: Short-course neoadjuvant erlotinib, particularly with celecoxib, is feasible, safe, and biologically active in operable OCSCC, supporting further evaluation to prevent progression during unavoidable surgical delays.